The Hidden Nasty In AstraZeneca plc’s Latest Results

AstraZeneca plc (LON:AZN) is a fine company, but Roland Head has noticed a disturbing trend in the firm’s clinical trials that investors should be aware of.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN) (NYSE: AZN.US) is a firm that I rate highly, but I recently discovered a ‘hidden nasty’ in the firm’s operations, which I feel potential shareholders should be aware of.

In this case, the problem isn’t financial — indeed, Astra’s balance sheet, which has minimal debt and plenty of cash, looks much more attractive than GlaxoSmithKline‘s debt mountain.

However, Astra’s earnings keep falling, as key products lose patent protection without being replaced by new products. My hidden nasty suggests that Astra is going to have to do some serious spending if it is to overcome this challenge in the next couple of years.

Phase lag

When a pharmaceutical company develops a new medicine, it goes through three sets of trials — phase 1, phase 2 and phase 3.

The majority of phase 1 and 2 trials don’t result in products that make it through to production, so as investors, it makes sense to concentrate our attention on phase 3 trials, around three-quarters of which do result in commercial products.

I’ve taken a look at the latest published pipeline documents for both AstraZeneca and Glaxo, and I’ve noticed what I believe to be a significant difference.

Approximately 30% of Glaxo’s current clinical trials are in phase 3, compared to just 15% of Astra’s.

When you consider that even after a successful phase 3 trial, medicines require regulatory approval, and can take several more years to reach the market, you can see what a mountain AstraZeneca has to climb in order to replace core products such as Nexium and Seroquel IR.

The fact that such a small proportion of Astra’s trials are in late stages is worrying for future revenues, and to me, this suggests that Astra’s pipeline is lagging significantly behind that of Glaxo.

Worth the wait?

AstraZeneca currently trades on a forecast P/E of 11.7 and offers a prospective yield of 4.8%. I think that’s an appealing valuation, despite the fact that Astra’s earnings per share are expected to fall by a further 9% this year, placing it on a 2014 forecast P/E of 12.8.

As a long-standing Glaxo shareholder, I’m going to sit tight, but if I were starting afresh today, I would almost certainly choose to invest in AstraZeneca, thanks to its strong balance sheet and cheap valuation. Over the medium term, history suggests that these attributes will provide above-average returns.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Roland owns shares in GlaxoSmithKline but does not own shares in AstraZeneca. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »